GW Pharma shares trading higher in opposition to Zogenix shares. Following news Zogenix received a refusal to file letter from the FDA for its drug candidate to treat seizures related to Dravet Syndrome, traders may be viewing GW as a sympathy play.
Benzinga Newsdesk